| Name | XMD-17-51 Trifluoroacetate |
| Description | XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases. |
| In vitro | XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound proficient in modulating an extensive range of protein kinases, such as MPS1 (TTK), ERK5 (BMK1, MAPK7), various polo kinases, Ack1, Ack2, Abl and its mutants, DCAMKL1, ABL1, DCAMKL2, and many others including Bcr-Abl, GAK, cSrc, and Trk family proteins. This versatility renders it applicable in treating a diverse array of diseases, disorders, or conditions [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 8 mg/mL (15.43 mM), Sonication is recommended. H2O : 2 mg/mL (3.86 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (6.36 mM), Sonication is recommended. DMSO : 80 mg/mL (154.29 mM), Sonication is recommended.
|
| Keywords | XMD-17-51 Trifluoroacetate | XMD1751 Trifluoroacetate | XMD 17 51 Trifluoroacetate | NUAK1 | 1628614-50-5 free base | 1628614-50-5 |
| Inhibitors Related | TBHQ | Urea | Gum arabic | L-Cysteine | Lactose | Dasatinib | Magnesium acetate tetrahydrate | Chromium(III) acetate | Gluconate Calcium | Chitosan oligosaccharide | Isovaleric acid | Danthron |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Anti-Fibrosis Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | AMPK-Targeted Compound Library |